Michael Mangone

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Changchun Deng, Mark Lipstein, Luigi Scotto et al. · Blood · 2016 · 105 citations · Full text

Medicine, Cancer Biology, Oncology +14

Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma

Kelly Zullo, Yige Guo, Laurence Cooke et al. · Clinical Cancer Research · 2015 · 47 citations

Medicine, Cancer Biology, Oncology +14

Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients.

Nikoletta Lendvai, Sacha Gnjatic, Erika Ritter et al. · PubMed · 2010 · 37 citations · Full text

Life Sciences, Immunology, Oncology +17

Pralatrexate Pharmacology and Clinical Development

Enrica Marchi, Michael Mangone, Kelly Zullo et al. · Clinical Cancer Research · 2013 · 34 citations

Medicine, Oncology, Pharmacology +13

The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma

Cristina Kinahan, Michael Mangone, Luigi Scotto et al. · Oncotarget · 2020 · 14 citations · Full text

Medicine, Oncology, Pharmacology +14